EDNRA and chronic kidney disease: These trials performed with various ETA antagonists show reno-protective effects by reducing proteinuria in patients with chronic kidney disease and type 2 diabetes [12, 21, 22, 34, 36, 42, 54, 61] which shows us that the results from a selective, cell-specific deletion of the ET receptors in the animal model are hardly transferable to human kidney diseases.